NINDS Exploratory/Developmental Projects in Translational Research (R21) | Apply Online

FAQs: NINDS Exploratory/Developmental Projects in Translational Research (R21) - PAR 08-232

What is the NINDS Exploratory/Developmental Projects in Translational Research (R21) opportunity?

It is a National Institutes of Health (NIH) grant program from the National Institute of Neurological Disorders and Stroke (NINDS) that supports early, practical translational research steps needed to move a potential therapy for a neurological disorder further along the preclinical development pipeline.

What is the main purpose of this R21 funding opportunity?

The purpose is to fund targeted, development-oriented work that reduces risk and prepares a candidate therapy for a follow-on project intended to complete the remaining work needed to support submission of an Investigational New Drug (IND) application or an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA).

What stage of research is this FOA intended to support?

This opportunity is intended for preclinical translational development work. It focuses on concrete steps that position a therapeutic candidate for the next major development stage (a subsequent IND- or IDE-enabling effort).

Does this opportunity support basic science or disease mechanism studies?

No. A defining feature of this FOA is that it only supports activities that are directly required for therapy development. It is not meant for basic science discovery, broad exploratory biology, or studies aimed at understanding disease mechanisms for their own sake.

Does this FOA support clinical research?

No. Clinical research is excluded under this opportunity based on the information provided.

What types of projects are considered a good fit for this FOA?

Projects that are framed around concrete translational milestones within a preclinical therapeutic development trajectory, with clear relevance to planning for eventual regulatory submission (IND or IDE). The work should be development-oriented and tied to specific deliverables that immediately feed into a later IND/IDE-enabling project if successful.

What is meant by "translational milestones" in the context of this FOA?

Within the information provided, translational milestones refer to practical, measurable development steps and deliverables that move a therapeutic candidate forward in the preclinical pipeline and reduce risk before launching a broader IND- or IDE-enabling program.

How does this R21 relate to an IND or IDE submission?

The R21 is meant to support early, targeted work that positions a therapy for a subsequent project that would carry out the remaining work needed to support an IND (for drugs/biologics) or IDE (for devices) submission to the FDA.

Is the goal to complete an IND or IDE submission within the R21 project?

The information emphasizes that the R21 prepares a candidate for a follow-on project that completes the IND- or IDE-enabling package. It is designed to fund early steps that lead naturally and immediately into that later, more comprehensive effort.

What funding mechanism is used for this opportunity?

The mechanism is the NIH R21 Exploratory/Developmental Grant, commonly used for early-stage, milestone-driven work that can be completed within a limited budget and time window compared with larger project grants.

What is the posted award ceiling for this opportunity?

The posted award ceiling is $200,000.

Can award size or project duration vary?

Yes. The announcement notes that award size and duration may vary because proposed projects can differ significantly in scope and cost, and the total number of awards depends on the quality and budget needs of the applications received.

Is cost sharing or matching required?

No. There is no cost sharing or matching requirement.

Who is eligible to apply?

Eligibility is broad and includes academic institutions (public and private), nonprofits (501(c)(3) and non-501(c)(3)), for-profit organizations (including small businesses and other for-profits), and multiple levels of government (state, county, city/township, special district, and independent school districts). It also includes tribal governments and tribal organizations, public housing authorities/Indian housing authorities, and additional categories such as HBCUs, Hispanic-serving institutions, TCCUs, Alaska Native and Native Hawaiian Serving Institutions, faith-based or community-based organizations, U.S. territories or possessions, regional organizations, eligible federal agencies, and non-U.S. (foreign) entities.

Are for-profit organizations eligible?

Yes. For-profit organizations, including small businesses and other for-profits, are included among the eligible applicant types listed.

Are non-U.S. (foreign) entities eligible?

Yes. Non-U.S. (foreign) entities are included in the eligibility categories described.

Are tribal governments and tribal organizations eligible?

Yes. Tribal governments and tribal organizations are explicitly included in the eligibility list.

Are institutions such as HBCUs, Hispanic-serving institutions, and TCCUs eligible?

Yes. Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, and Tribally Controlled Colleges and Universities (TCCUs) are included among eligible entities.

Which agency sponsors this funding opportunity?

The sponsoring agency is the National Institutes of Health (NIH), with the program associated with NINDS.

What is the Funding Opportunity Number for this announcement?

The Funding Opportunity Number is PAR 08-232.

What is the CFDA number associated with this program?

The program is associated with CFDA number 93.853, titled "Extramural Research Programs in the Neurosciences and Neurological Disorders."

When was this opportunity posted and when did it close?

It was posted on August 12, 2008. The original and final closing date was September 7, 2011, and the archive date was October 8, 2011.

Where was the full announcement published?

The full announcement was made available through the NIH Grants Guide (as referenced in the source information).

Who should be contacted for support with access or linking issues related to the announcement?

Support for access or linking issues is routed through the NIH Office of Extramural Research (OER) webmaster contact.

What is the overall emphasis of this FOA compared with broader research grants?

The emphasis is on translational, development-required activities tied to concrete deliverables that reduce risk and prepare a therapeutic candidate for the next development stage, rather than broad discovery science or clinical studies.